Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis.
Caballero T, Baeza ML, Cabañas R, Campos A, Cimbollek S, Gómez-Traseira C, González-Quevedo T, Guilarte M, Jurado-Palomo GJ, Larco JI, López-Serrano MC, López-Trascasa M, Marcos C, Muñoz-Caro JM, Pedrosa M, Prior N, Rubio M, Sala-Cunill A; Spanish Study Group on Bradykinin-Induced Angioedema; Grupo Español de Estudio del Angioedema mediado por Bradicinina. Caballero T, et al. J Investig Allergol Clin Immunol. 2011;21(5):333-47; quiz follow 347. J Investig Allergol Clin Immunol. 2011. PMID: 21905496 Free article. Review.
Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part II. Treatment, follow-up, and special situations.
Caballero T, Baeza ML, Cabañas R, Campos A, Cimbollek S, Gómez-Traseira C, González-Quevedo T, Guilarte M, Jurado-Palomo J, Larco JI, López-Serrano MC, López-Trascasa M, Marcos C, Muñoz-Caro JM, Pedrosa M, Prior N, Rubio M, Sala-Cunill A; Spanish Study Group on Bradykinin-Induced Angioedema (SGBA). Caballero T, et al. J Investig Allergol Clin Immunol. 2011;21(6):422-41; quiz 442-3. J Investig Allergol Clin Immunol. 2011. PMID: 21995176 Free article. Review.
Fatal Anaphylactic Shock Induced by Intravenous Gelatin Colloid: A Postmortem Allergological Work-up.
Molina-Molina GJ, Carrasco-González MD, Viñas-Giménez L, Sanz-Martínez M, Galván-Blasco P, Luengo O, Guilarte M, Sala-Cunill A, Cardona V, Labrador-Horrillo M. Molina-Molina GJ, et al. J Investig Allergol Clin Immunol. 2020 Apr 24;30(2):143-145. doi: 10.18176/jiaci.0459. Epub 2019 Oct 10. J Investig Allergol Clin Immunol. 2020. PMID: 31599728 Free article. No abstract available.
Co-factor-enhanced food allergy.
Cardona V, Luengo O, Garriga T, Labrador-Horrillo M, Sala-Cunill A, Izquierdo A, Soto L, Guilarte M. Cardona V, et al. Allergy. 2012 Oct;67(10):1316-8. doi: 10.1111/j.1398-9995.2012.02877.x.. Epub 2012 Jul 30. Allergy. 2012. PMID: 22845005
ALERGODATA: Sentinel Registry of Health Outcomes in Allergic Patients Treated With Biological Therapies at Specialized Allergology Clinics in Spain.
Antolín Amérigo D, Colás C, Dávila I, Del Cuvillo A, Delgado Romero J, Domínguez-Ortega J, Jáuregui Presa I, Lázaro Sastre M, Montoro Lacomba J, Sala-Cunill A, Sanchez-Garcia S, Veleiro Pérez B, Vidal C, Valero Santiago AL. Antolín Amérigo D, et al. Among authors: sala cunill a. J Investig Allergol Clin Immunol. 2023 Dec 14;33(6):479-482. doi: 10.18176/jiaci.0908. Epub 2023 May 15. J Investig Allergol Clin Immunol. 2023. PMID: 37183958 Free article. No abstract available.
Profile of Patients With Moderate-to-Severe Atopic Dermatitis and Chronic Urticaria Undergoing Biological Treatment in Hospital Allergy Units in Spain: First Report of the Alergodata Registry.
Jáuregui Presa I, Sala-Cunill A, Martí-Garrido J, Nieto Cid M, Corrales Vargas SI, Lizarza Mendizábal S, Asensio Sánchez MT, Ribó González P, Quirce S, Sánchez Hernández MC, Joral Badas A, Vidal C, Antolín-Amérigo D, Veleiro B, Lázaro Sastre M; Alergodata Skin Diseases Study Group. Jáuregui Presa I, et al. Among authors: sala cunill a. J Investig Allergol Clin Immunol. 2024 Apr 12;34(2):131-133. doi: 10.18176/jiaci.0945. Epub 2023 Oct 31. J Investig Allergol Clin Immunol. 2024. PMID: 37905432 Free article. No abstract available.
Efficacy and Safety of Omalizumab (Xolair) for Cholinergic Urticaria in Patients Unresponsive to a Double Dose of Antihistamines: A Randomized Mixed Double-Blind and Open-Label Placebo-Controlled Clinical Trial.
Gastaminza G, Azofra J, Nunez-Cordoba JM, Baeza ML, Echechipía S, Gaig P, García BE, Labrador-Horrillo M, Sala-Cunill A, Brescó MS, Beristain A, Quiñones D, Donado CD, Zubeldia JM, Ferrer M. Gastaminza G, et al. J Allergy Clin Immunol Pract. 2019 May-Jun;7(5):1599-1609.e1. doi: 10.1016/j.jaip.2018.12.025. Epub 2019 Jan 15. J Allergy Clin Immunol Pract. 2019. PMID: 30654196 Clinical Trial.
Omalizumab for the treatment of chronic inducible urticaria in 80 patients.
Exposito-Serrano V, Curto-Barredo L, Aguilera Peiro P, Gómez Armayones S, Serra-Baldrich E, Spertino J, Bonfill Ortí M, Figueras Nart I, Melé-Ninot G, Baliu-Piqué C, Sala Cunill A, Labrador-Horrillo M, Guilabert Vidal A, Fernández Chico N, Giménez-Arnau AM. Exposito-Serrano V, et al. Br J Dermatol. 2021 Jan;184(1):167-168. doi: 10.1111/bjd.19425. Epub 2020 Sep 2. Br J Dermatol. 2021. PMID: 32730636 No abstract available.
46 results